# RTX001 Autologous Engineered Macrophages for Liver Cirrhosis

> **NCT06823713** · PHASE1,PHASE2 · RECRUITING · sponsor: **Resolution Therapeutics Limited** · enrollment: 30 (estimated)

## Conditions studied

- End-stage Liver Disease (ESLD)
- Cirrhosis, Liver
- Cirrhosis, Decompensated
- Liver Diseases
- Fibrosis and Cirrhosis of Liver
- Decompensated Liver Cirrhosis
- Decompensated Cirrhosis
- Steatotic Liver Disease

## Interventions

- **DRUG:** RTX001

## Key facts

- **NCT ID:** NCT06823713
- **Lead sponsor:** Resolution Therapeutics Limited
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-15
- **Primary completion:** 2028-08-29
- **Final completion:** 2028-11-29
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06823713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06823713, "RTX001 Autologous Engineered Macrophages for Liver Cirrhosis". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06823713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*